المؤلفون: Ilardo, Claudio¹ calogero.ilardo@labosud.fr, Al Muhanna, Batricia², Lamarti, Chèhine²

المصدر: International Journal of Medical Biochemistry. 2025, Vol. 8 Issue 1, p39-44. 6p.

مصطلحات موضوعية: *HEMOLYSIS & hemolysins, *LIPASES, *BLOOD serum analysis, *HYDROLASES

الشركة/الكيان: ROCHE Diagnostics AG

المؤلفون: Obaid, Jamil MAS (AUTHOR), Sakran, Khawla AAS (AUTHOR), Mohammed, Shaima AH (AUTHOR), Al-Salahi, Shifa'a LA (AUTHOR), Mahdi, Nawal AN (AUTHOR), AL-Sharabi, Mohammed AM (AUTHOR), AL-Gaadi, Asadaddin SM (AUTHOR), AL-Fatahi, Mohammed NM (AUTHOR)

المصدر: Journal of Blood Medicine. Oct2024, Vol. 15, p459-469. 11p.

مصطلحات موضوعية: *LOW-income countries, *HEMOLYSIS & hemolysins, *BLOOD banks, *BLOOD transfusion, *HEMOGLOBINS

المصدر: Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

المصدر: Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

المصدر: Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

المصدر: A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

المصدر: A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Other URLs: https://www.janssen.com/clinical-trials/transparency

المصدر: Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With a Long-term Open-label Extension
Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012493. doi: 10.1002/14651858.CD012493.pub2.

المؤلفون: Chugai Pharmaceutical

المصدر: A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

المصدر: A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

المؤلفون: China Immunotech (Beijing) Biotechnology Co., Ltd.

المساهمون: Jun Shi, Director of the Red Blood Cell Disorders Center & Director of the Regenerative Medicine Clinic

المصدر: The Safety and Efficacy of YTS109 Cell Injection for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy.

المصدر: A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Chinese Atypical Hemolytic Uremic Syndrome Patients

Other URLs: https://vivli.org/

المؤلفون: Chugai Pharmaceutical

المصدر: A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

المساهمون: Fatema Sulaiman Alhazmi, Cilinical fellow, Madinah Maternity and Children's Hospital, NICU

المصدر: Safe Threshold to Discontinue Phototherapy in Term and Late Preterm Infant With Hemolytic Disease of Newborn: A Randomized Controlled Trial

المصدر: A Multicenter, Single Arm, Open-label Study to Evaluate Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With aHUS

المصدر: A Multi-center, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Iptacopan in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Who Have Completed a Preceding Iptacopan Phase 3 Study in aHUS

المساهمون: Saadiea Abdo Bedir Eid, Principal investigator

المصدر: Predisposing Factors for Liver Diseases in Patients With Chronic Hemolytic Anemia

المصدر: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

Other URLs: https://www.incyte.com/our-company/compliance-and-transparency

المصدر: Nipocalimab Post-trial Access in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA) Who Are Experiencing Clinical Benefit After Complete 28-Weeks Open-label Extension in MOM-M281-006

المصدر: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With An Open Label Safety and Dose Confirmation Run-In Period, To Evaluate the Efficacy and Safety of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)